

### AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application.

#### **Listing of Claims:**

1. (Canceled)
2. (Canceled)
3. ~~The packaged pharmaceutical of claim 2,~~ A packaged pharmaceutical composition to treat berylliosis in a subject comprising a container that holds a therapeutically effective amount of at least one porphyrin analogue and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein the porphyrin analogue or pharmaceutically acceptable salt, ester, amide, or prodrug thereof is administered as an aerosol; and  
  
instructions for use of the porphyrin analogue for the treatment of berylliosis in the subject.
4. (Previously presented) The packaged pharmaceutical of claim 3, wherein the aerosol is administered in conjunction with an inhaler.
5. (Currently amended) The packaged pharmaceutical of claim ~~2~~ 3, wherein the porphyrin analogue is hemin, meso-tetra (4-carboxyphenyl) porphyrin, phthalocyanine tetrasulfonate, meso-tetra (4-sulfonatophenyl) porphyrin, or magnesium phthalocyanine tetrasulfonate tetra sodium salt porphyrin.
6. (Currently amended) The packaged pharmaceutical of claim ~~2~~ 3, wherein the porphyrin analogue comprises at least 4 interconnected heteroatoms in an organic structure that provides a binding site for a metal ion associated with berylliosis.
7. (Previously presented) The packaged pharmaceutical of claim 6, wherein the heteroatoms are each independently nitrogen, oxygen, sulfur, or selenium and combinations thereof.

8. (Previously presented) The packaged pharmaceutical of claim 7, wherein each of the four heteroatoms are nitrogen atoms.

9. (Previously presented) The packaged pharmaceutical of claim 7, wherein at least two of the four heteroatoms are nitrogen atoms.

10. (Previously presented) The packaged pharmaceutical of claim 7, wherein the porphyrin analogue has at least one functional group appended thereto.

11. (Previously presented) The packaged pharmaceutical of claim 10, wherein the functional group comprises a sulfur moiety.


12. (Previously presented) The packaged pharmaceutical of claim 11, wherein the sulfur moiety is a sulfonate.

13. (Previously presented) The packaged pharmaceutical of claim 10, wherein the functional group comprises a carboxylate.

14. (Previously presented) The packaged pharmaceutical of claim 13, wherein the porphyrin analogue chelates the metal ion associated with berylliosis.

15. (Previously presented) The packaged pharmaceutical of claim 14, wherein the metal ion is an element, a metal oxide, a mineral or a metal salt.

16. (Previously presented) The packaged pharmaceutical of claim 6, wherein the porphyrin analogue has the following formula (Formula I):



Formula I

wherein each A, independently, is a heteroatom;

each Z, independently, is a carbon atom or a heteroatom;

each Y, independently, is a hydrogen atom, a functional group or when Z is a heteroatom, forms part of a double bond;


S and T are each, independently, a functional group or together form a ring;

and each n is an integer of 1 or 2 to complete the carbon chain.

17. (Previously presented) The packaged pharmaceutical of claim 16, wherein each A is a nitrogen atom, each Z is a nitrogen atom or a carbon atom, S and T together form a pyrrole or a phenyl group, and  $n = 1$ , wherein the pyrrole or phenyl group is substituted with at least one sulfur containing moiety.

18. (Previously presented) The packaged pharmaceutical of claim 17, wherein the sulfur containing moiety is a sulfonate.

19. (Previously presented) The packaged pharmaceutical of claim 6, wherein the porphyrin analogue has the following formula (Formula II):



Formula II

wherein each A, independently, is a heteroatom;

each Z, independently, is a carbon atom or a heteroatom;

each Y, independently, is a hydrogen atom, a functional group or when Z is a heteroatom, forms part of a double bond; and

S and T are each, independently, a functional group or together form a ring.

20. (Previously presented) The packaged pharmaceutical of claim 19, wherein each A is a nitrogen atom, each Z is a nitrogen atom or a carbon atom, S and T together form a pyrrole or a phenyl group, and wherein the pyrrole or phenyl group is substituted with at least one sulfur containing moiety.

21. (Previously presented) The packaged pharmaceutical of claim 20, wherein the sulfur containing moiety is a sulfonate.